Biocon Ltd, the Bengaluru-based biopharmaceutical major, has reported a sharp 56.8% decline in its consolidated net profit for the fourth quarter ended March 31, 2026. The company’s net profit stood at ₹198.6 crore, compared to ₹459.4 crore in the corresponding period of the previous fiscal year. The significant drop in earnings was primarily attributed to an exceptional item outgo of ₹80.4 crore, which included the financial impact of the new labour code and other specific adjustments.
Despite the pressure on the bottom line, consolidated revenue from operations remained relatively stable. Biocon reported revenue of ₹4,516.6 crore for the quarter, marking a slight increase from the ₹4,417 crore recorded in the same period last year. However, this marginal growth was offset by rising operational costs. Total expenses for the fourth quarter climbed to ₹4,241.2 crore, up from ₹3,987.5 crore a year ago, reflecting the broader inflationary pressures and increased manufacturing or compliance costs within the industry.
In a regulatory filing on Thursday, the company confirmed that its board has recommended a final dividend of 50 paise per equity share with a face value of ₹5 for the financial year. This recommendation is subject to approval by shareholders at the upcoming Annual General Meeting. While the quarterly profit was hit by one-off expenses and regulatory shifts, the dividend suggests a focus on maintaining shareholder returns. Market analysts remain focused on Biocon’s biosimilars segment and its research and development pipeline to drive future growth and stabilize margins as it navigates these immediate fiscal headwinds.
